

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(Incorporated in Bermuda with limited liability)

(Stock code: 0233)

INSIDE INFORMATION

This announcement is made by Mingyuan Medicare Development Company Limited (the “**Company**”) pursuant to Rules 13.09(2) and 13.24A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated 31 March 2015 in relation to, amongst other things, the suspension of trading in the shares of the Company (the “**Shares**”) on the Stock Exchange; (ii) the announcement of the Company dated 15 July 2015 in relation to the conditions for resumption of trading in the Shares imposed by the Stock Exchange (the “**Resumption Conditions**”); (iii) the announcement of the Company dated 24 October 2017 in relation to the direction given by the Securities and Futures Commission to the Stock Exchange under Rule 8(1) the Securities and Futures (Stock Market Listing) Rules (“**SMLR**”) to suspend all dealings in the Shares; and (iv) the announcement of the Company dated 10 August 2018 in relation to an update on trading suspension.

RESUMPTION PROGRESS

Progress in Fulfilling the Resumption Conditions

The Company has been giving priority to publish all outstanding financial results under the Listing Rules, and has been cooperating with its auditors to attain the same, including addressing any audit qualifications. The Company has recently been informed that the audit works for the years 2014 to 2016 will be completed by the end of November 2018, whilst the completion of audit works for the year 2017 will be completed by the end of December 2018. The Company shall inform shareholders timely on the expected time frame for the publication of the outstanding financial results.

** For identification purpose only*

Pursuant to Article 67 of the New Bye-Laws of the Company, the Company shall in each year hold a general meeting as its annual general meeting. The Company will convene an annual general meeting on 9 November 2018 (the “AGM”) to transact the business as set out in Article 73 of the New Bye-Laws despite the audited financial statements for the year ended 31 December 2014, 31 December 2015, 31 December 2016 and 31 December 2017 are still under preparation. Shareholders shall refer to the Circulars and the Notice of Annual General Meeting published in the Stock Exchange website on 10 October 2018 for the details of the arrangements for the AGM.

BUSINESS UPDATE

As at the date of this announcement, the Health Care Division which is responsible for manufacturing and trading of HPV DNA testing kits has been carrying on its business as usual and continuing to explore its distribution network nationwide and worldwide.

In relation to the business operated/controlled by the two Shanghai subsidiaries, Shanghai Health Digit and SHMY Biochip, the Board is unable to provide information on their operation given that the Company is still in the process of restoring its control over these two subsidiaries.

CONTINUED SUSPENSION OF TRADING

The Company will keep its shareholders and potential investors informed of any material development in connection with the above matters, including but not limited to, any material changes to the resumption progress, by way of quarterly announcements and/or further announcements as and when appropriate. Trading in the Shares on the Stock Exchange will remain suspended until further notice.

By Order of the Board
Mingyuan Medicare Development Company Limited
LAM Ping Cheung
Chairman

Hong Kong, 6 November 2018

As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors; (ii) Ms. Chan Mee Sze, Mr. Lam Suk Ping, Mr. Cheung Chi Ming and Ms. Fan Stephanie Winnie as independent non-executive Directors.